Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rebio Technologies OY currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is being reviewed by 1 distinct examiner in 1 distinct art unit, reflecting a very narrow prosecution focus. For a practitioner, this means the entire active portfolio is subject to the standards of 1 distinct art unit within the Biotechnology & Pharmaceuticals technology area. This centralization can be beneficial for maintaining a consistent narrative across the company's intellectual property filings, as there are no conflicting examiner viewpoints to reconcile at this stage.
The busiest examiner, MACH, ANDRE, is assigned 1 busiest examiner pending action. Since this 1 busiest examiner pending action is the only one pending for the company, the prosecution strategy must be tailored specifically to the expectations of MACH, ANDRE. The outcome of this 1 distinct examiner's review will determine the immediate success of the company's efforts in the Biotechnology & Pharmaceuticals technology area. Practitioners should focus on the specific technical nuances required by the 1 distinct art unit to effectively navigate the examination process and secure the desired patent protection for their innovations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278017 | Compositions for ophthalmic care | MACH, ANDRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278017 | Compositions for ophthalmic care | MACH, ANDRE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278017 | Compositions for ophthalmic care | MACH, ANDRE | 1615 | §102§103 | Final Rejection | — | Pending | Aug 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial